Clinical Trials Browser

Brain Neoplasms × osimertinib × Thoracic × Clear all

NCT02971501 2026-05-29

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

5 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07491211 2026-03-27

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Active not recruiting

300 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07206498 2025-11-28

WAYWIN103

Phase 1/2 Recruiting

48 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03769103 2024-10-31

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

Phase 2 Active not recruiting

40 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Phase 2 Not yet recruiting

255 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02736513 2021-09-02

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

Phase 2 Unknown

40 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT02228369 2021-01-05

BLOOM

Phase 1 Completed

108 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02972333 2016-11-23

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Phase 3 Unknown

150 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung